Adaptimmune Therapeutics Plc (ADAP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adaptimmune Therapeutics Plc (ADAP) has a cash flow conversion efficiency ratio of 0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-34.78 Million) by net assets ($-70.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Adaptimmune Therapeutics Plc to measure how much of total assets are equity-financed.
Adaptimmune Therapeutics Plc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Adaptimmune Therapeutics Plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Adaptimmune Therapeutics Plc to evaluate the quality of earnings relative to operating cash generation.
Adaptimmune Therapeutics Plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptimmune Therapeutics Plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manhattan Corporation Ltd
AU:MHC
|
-0.037x |
|
Ryukil C&S Ltd
KQ:191410
|
-0.033x |
|
K2 Asset Management Holdings Ltd
AU:KAM
|
0.052x |
|
Arbor Metals Corp
V:ABR
|
-0.006x |
|
Energoinstal S.A.
WAR:ENI
|
0.031x |
|
CWG Holdings Bhd
KLSE:9423
|
0.098x |
|
Encorp Bhd
KLSE:6076
|
0.379x |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
-0.076x |
Annual Cash Flow Conversion Efficiency for Adaptimmune Therapeutics Plc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Adaptimmune Therapeutics Plc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see ADAP market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $11.85 Million | $-73.21 Million | -6.178x | -73.28% |
| 2023-12-31 | $39.51 Million | $-140.88 Million | -3.565x | -105.92% |
| 2022-12-31 | $81.88 Million | $-141.77 Million | -1.731x | -3423.82% |
| 2021-12-31 | $205.96 Million | $10.73 Million | 0.052x | +133.17% |
| 2020-12-31 | $341.23 Million | $-53.59 Million | -0.157x | +82.74% |
| 2019-12-31 | $123.64 Million | $-112.51 Million | -0.910x | -115.21% |
| 2018-12-31 | $246.88 Million | $-104.39 Million | -0.423x | -58.01% |
| 2017-12-31 | $202.98 Million | $-54.31 Million | -0.268x | +7.70% |
| 2016-12-31 | $166.14 Million | $-48.17 Million | -0.290x | -129.92% |
| 2015-12-31 | $259.61 Million | $-32.74 Million | -0.126x | +0.00% |
| 2014-12-31 | $259.61 Million | $-32.74 Million | -0.126x | -100.82% |
| 2013-12-31 | $2.41 Million | $37.23 Million | 15.449x | +328.86% |
| 2012-12-31 | $-2.16 Million | $-7.77 Million | 3.602x | -- |
About Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more